Cambridge Cognition Holdings plc has reported a drop in revenue in its latest annual results.

For the 12 months to 31st December 2025, revenues were £9.4m, down 10% on the prior year. Its adjusted EBITDA loss was in line with market expectations (2024: loss of £43k).

The neuroscience technology company, whose digital cognitive assessments drive scientific discovery, accelerate drug development and improve patient care, said however that new sales orders in the year were up 73% to £12.8m (2024: £7.4m), while the order book at year end was up 25% to £16.9m (2024: £13.6m).

The firm raised £1.1m via a share placing in August. Rob Baker was appointed CEO two months ago.